Hello everyone! If you've been using decentralized applications (DApps), you likely appreciate the convenience of an all-in-one crypto asset management platform. Instead of juggling multiple platforms, you can log in once and execute investment strategies or allocate funds to high-performing vaults—all within a single protocol.
Enzyme Finance (MLN) was built to meet these seemingly simple needs. In this article, let’s explore and evaluate Enzyme’s standout features.
Overview of Enzyme (MLN)
Enzyme Finance (rebranded from Melon Protocol but retaining the $MLN token) is a decentralized asset management protocol. Its goal is to enable anyone, anywhere, with any amount of capital, to invest in a decentralized manner. Additionally, fund managers can create their own investment vaults on Enzyme to track portfolio performance and expand strategies using external capital.
For retail investors, Enzyme offers trustless access to high-yield investment vaults—without handing over funds to centralized entities.
👉 Discover how Enzyme optimizes asset management advantages
Key Metrics
- 254 vaults managing $8.3M in assets.
- Largest vault: Rhino Fund ($3.8M).
Tokenomics (MLN)
Originally, Melon Protocol’s tokenomics were inefficient:
- Annual inflation: 300,600 MLN (uncapped), leading to price depreciation.
In June 2020, the team proposed MIP7, a overhaul plan:
- Yearly issuance reduction: 20% until near-zero.
- Dev incentives: Issued tokens are used for team payouts, with excess burned.
Fee structure:
- 0.1% per investment.
- 0.2% management fee (discounted for MLN holders).
What Makes Enzyme Unique?
Sulu Update
Recent upgrades include:
- Borrowing: Leverage positions for higher yields.
- Vault token transfers.
- ETH staking and multi-protocol yield farming.
- Integrations: Aave, Curve, Balancer.
Portfolio Management
- Supports 150+ crypto assets.
- Tools for lending, synthetic assets, and AMMs.
MIP7 Plan
- ETH fees buy back and burn MLN.
- No upfront costs for vault creation.
Team & Integrations
Backed by Avantgarde Finance (CEO: Mona el Isa), Enzyme focuses on long-term growth through DeFi partnerships (e.g., Aave, Curve).
Growth Potential
Token Value/TVL
- Market cap: $45M.
- TVL: $8M (potential 3x growth with Rari Capital’s $16M vault).
Competitor: dHedge (DHT)
- Similar model but built on Synthetix.
- Enzyme supports more assets (150 vs. 50) and offers deeper customization.
Technical Analysis
- MLN/ETH: Near June 2020 lows, showing recovery signs.
- MLN/USD: Short-term downtrend; wait for better entry points.
Conclusion
Enzyme’s rebranding and MIP7 reforms position MLN for potential growth. Will it regain its past highs? Share your thoughts below!
FAQ
1. What is Enzyme Finance?
A decentralized platform for creating and managing crypto investment vaults.
2. How does MLN’s tokenomics work post-MIP7?
Yearly issuance reduces by 20%, with excess tokens burned.
3. Which protocols integrate with Enzyme?
Aave, Curve, Balancer, and more.